Want to see IN:ORCHPHARMA full AI Analyst Report?
Top Page
Orchid Pharma Limited
(ORCHPHARMA)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹1,026.00
▲(3.86% Upside)
Action:Reiterated
Date:09/22/26
The score is primarily held back by weaker recent financial performance and inconsistent cash generation (including recurring negative free cash flow), alongside a very high P/E that increases valuation risk. These are partially offset by strong technical strength, with the stock trading above key moving averages and showing positive momentum.
Positive Factors
Conservative Balance Sheet
Equity is substantially larger than debt and leverage has fallen from FY2021–FY2023 levels. This conservative financing profile can reduce balance-sheet strain, preserve borrowing capacity, and provide resilience while the company funds operations and future growth.
Negative Factors
FY2026 Revenue Decline
The FY2026 revenue decline interrupts the company’s prior multi-year expansion and indicates weaker demand, execution, or market conditions than in the preceding period. If sustained, lower revenue would constrain operating leverage, reinvestment capacity, and earnings recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Equity is substantially larger than debt and leverage has fallen from FY2021–FY2023 levels. This conservative financing profile can reduce balance-sheet strain, preserve borrowing capacity, and provide resilience while the company funds operations and future growth.
Read all positive factors
Orchid Pharma Limited (ORCHPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹59.38B
Dividend Yield16.67%
Average Volume (3M)7.00K
Price to Earnings (P/E)575.1
Beta (1Y)1.34
Revenue Growth10.83%
EPS Growth-89.82%
CountryIN
Employees1,169
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.71
Shares Outstanding59,885,200
10 Day Avg. Volume11,466
30 Day Avg. Volume7,005
Financial Highlights & Ratios
PEG Ratio-1.50
Price to Book (P/B)1.90
Price to Sales (P/S)3.02
P/FCF Ratio-8.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8
Revenue Forecast (FY)₹12.88B
Orchid Pharma Limited Business Overview & Revenue Model
Company Description
Operating primarily within India, Orchid Pharma Limited is a pharmaceutical firm specializing in the creation, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and nutraceutical products....
Orchid Pharma Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
72
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.43B | 8.11B | 9.22B | 8.19B | 6.66B | 5.60B |
| Gross Profit | 2.43B | 1.59B | 3.55B | 1.36B | 706.89M | 2.32B |
| EBITDA | 502.20M | 411.28M | 1.45B | 1.42B | 1.43B | 621.38M |
| Net Income | 86.67M | 205.47M | 996.57M | 921.66M | 463.18M | -19.51M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 19.11B | 16.88B | 15.54B | 12.25B | 11.11B |
| Cash, Cash Equivalents and Short-Term Investments | 832.11M | 840.74M | 1.83B | 45.24M | 275.21M | 48.27M |
| Total Debt | 0.00 | 3.63B | 1.75B | 1.35B | 3.31B | 2.68B |
| Total Liabilities | -12.88B | 6.23B | 4.21B | 3.84B | 5.37B | 4.63B |
| Stockholders Equity | 12.88B | 12.88B | 12.67B | 11.69B | 6.89B | 6.47B |
Cash Flow | ||||||
| Free Cash Flow | -1.47B | -2.74B | -1.31B | 611.77M | -665.75M | 780.71M |
| Operating Cash Flow | 115.10M | 1.10B | 192.15M | 1.26B | 183.38M | 924.75M |
| Investing Cash Flow | -906.39M | -2.96B | -269.31M | -3.12B | -312.14M | 1.13B |
| Financing Cash Flow | 1.00B | 1.72B | 252.22M | 1.67B | 311.66M | -2.17B |
Orchid Pharma Limited Technical Analysis
Negative
987.90
Price Trends
1002.55
Negative
952.63
Positive
801.19
Positive
Market Momentum
4.15
Positive
42.67
Neutral
11.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORCHPHARMA, the sentiment is Negative. The current price of 987.9 is below the 20-day moving average (MA) of 1012.26, below the 50-day MA of 1002.55, and above the 200-day MA of 801.19, indicating a neutral trend. The MACD of 4.15 indicates Positive momentum. The RSI at 42.67 is Neutral, neither overbought nor oversold. The STOCH value of 11.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ORCHPHARMA.
Orchid Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹72.75B | 53.95 | ― | 0.22% | 20.59% | 27.16% | |
64 Neutral | ₹61.48B | 36.80 | ― | 0.48% | 18.56% | 60.06% | |
58 Neutral | ₹41.94B | 57.42 | ― | 0.02% | 16.70% | 18.73% | |
57 Neutral | ₹59.38B | 575.12 | ― | 16.67% | 10.83% | -89.82% | |
57 Neutral | ₹37.70B | 12.29 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹34.42B | -1,276.79 | ― | 0.45% | 15.49% | -112.78% |
* General Sector Average
IN:ORCHPHARMA
Orchid Pharma Limited
991.55
249.55
33.63%
IN:BLISSGVS
Bliss Gvs Pharma Limited
684.20
530.83
346.12%
IN:GUFICBIO
Gufic Biosciences Limited
418.20
63.54
17.91%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
209.45
106.89
104.22%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
716.00
105.05
17.19%
IN:UNICHEMLAB
Unichem Laboratories Limited
535.50
48.45
9.95%
Orchid Pharma Limited Corporate Events
Orchid Pharma Calls AGM to Ratify Post-Merger Financials and Key Governance Moves
Sep 7, 2026
Orchid Pharma Limited has released its annual report for the financial year 2025-26 and issued notice for its 33rd Annual General Meeting, scheduled for September 29, 2026, to be held via video conferencing and other audio-visual means. The AGM ag...
Orchid Pharma Files FY 2025-26 Business Responsibility and Sustainability Report
Sep 7, 2026
Orchid Pharma Limited, a Dhanuka Group company in the pharmaceutical sector, operates manufacturing facilities in Tamil Nadu and maintains a corporate office near Gurugram, reflecting a significant footprint in India’s healthcare and capital...
Orchid Pharma Board Sets Cost Auditor, Elevates Director and Finalizes AGM Framework
Sep 3, 2026
Orchid Pharma Limited’s board met on September 3, 2026 and approved several governance and compliance measures, including the appointment of M/s J Karthikeyan Associates as cost auditor for the financial year 2026-27, subject to shareholder...
Orchid Pharma Completes Dhanuka Laboratories Merger, Ups Authorised Capital
Jul 10, 2026
Orchid Pharma Limited has implemented a merger scheme under which Dhanuka Laboratories Limited has been amalgamated into the company, with the scheme effective from July 10, 2026 and Dhanuka dissolved without winding up. The appointed date of the ...
Orchid Pharma Finalizes Merger with Dhanuka, Boosts Authorised Capital and Sets Record Date
Jul 10, 2026
Orchid Pharma Limited has announced that the merger scheme with Dhanuka Laboratories Limited has become effective as of July 10, 2026, resulting in the dissolution of the amalgamating company without winding up. The appointed date of the scheme is...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.